Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response
Ovarian Hyperstimulation Syndrome
About this trial
This is an interventional treatment trial for Ovarian Hyperstimulation Syndrome focused on measuring OHSS, Mineralocorticoid, aldosterone
Eligibility Criteria
Inclusion Criteria: patients undergoing ICSI who were considered at risk of developing OHSS:
- polycystic ovaries and/or previous history of OHSS, AMH > 40 pmol/L but patients were finally included in the study if serum E2 levels reached >3000 pg/ml on day of hCG trigger or at any stage of folliculometry
- age: 18-40
Exclusion Criteria:
- retrieval of less than 20 oocytes
- age less than 18 or above 40
Sites / Locations
- Ganin Fertility Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Experimental
Experimental
Control group
treatment group
prevention group
patients at high risk for OHSS who are receiving conventional treatment either as a prophylaxis (in the form of bromocriptine) or as a management in case of developing OHSS (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy)
patient who has developed OHSS while on conventional lines of management (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy) patients in this group, fludrocortisone was added to conventional lines of management.
patients at high risk for OHSS who are receiving fludrocortisone as a prophylaxis